Fig. 2: iASPP-Deficient Mice are Less Susceptible to Experimental Autoimmune Encephalitis.
From: Regulation of immunological tolerance by the p53-inhibitor iASPP
A Schematic of experimental autoimmune encephalomyelitis (EAE) model and experimental design. Mice were monitored until 30 days after immunization with MOG/CFA or until reaching primary endpoint of bilateral hind limb paralysis (clinical severity score = 3). MOG, 200 μg MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK); CFA, Complete Freund’s Adjuvant supplemented with 400 μg H37Ra mycobacterium tuberculosis; PTx, 300 ng pertussis toxin. B Clinical course of MOG-induced EAE in WT (n = 7) or iASPP−/− (n = 10) mice. AUC, area under the curve. C Luxol fast blue (LFB), HE, and CD3 immunohistochemistry stains of corpus callosum, cerebellum, and spinal cord isolated from WT (n = 4) or iASPP−/− (n = 6) mice 30 days after immunization with MOG/CFA. Arrows indicate areas of demyelination. Scale, 1 mm (top) and 100 μm (bottom).
